Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PAHC
Previous Symbol
CUSIPN/A
Phone201-329-7300
Debt
Debt-to-Equity Ratio1.62
Current Ratio3.26
Quick Ratio1.82
Price-To-Earnings
Trailing P/E Ratio18.82
Forward P/E Ratio18.98
P/E Growth2.8
Sales & Book Value
Annual Sales$820 million
Price / Sales1.61
Cash Flow$2.4293 per share
Price / Cash Flow13.44
Book Value$4.58 per share
Price / Book7.13
Profitability
EPS (Most Recent Fiscal Year)$1.74
Net Income$64.88 million
Net Margins7.89%
Return on Equity38.91%
Return on Assets10.60%
Miscellaneous
Employees1,500
Outstanding Shares40,380,000
Market Cap$1.32 billion
OptionableOptionable
Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions
What is Phibro Animal Health's stock symbol?
Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."
How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?
Phibro Animal Health announced a quarterly dividend on Tuesday, November 6th. Investors of record on Wednesday, November 28th will be paid a dividend of $0.12 per share on Wednesday, December 19th. This represents a $0.48 dividend on an annualized basis and a yield of 1.47%. The ex-dividend date of this dividend is Tuesday, November 27th. This is an increase from Phibro Animal Health's previous quarterly dividend of $0.10. View Phibro Animal Health's Dividend History.
How were Phibro Animal Health's earnings last quarter?
Phibro Animal Health Corp (NASDAQ:PAHC) issued its earnings results on Tuesday, November, 6th. The company reported $0.39 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by $0.03. The company earned $200.20 million during the quarter, compared to the consensus estimate of $203.99 million. Phibro Animal Health had a net margin of 7.89% and a return on equity of 38.91%. The company's revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.38 EPS. View Phibro Animal Health's Earnings History.
When is Phibro Animal Health's next earnings date?
What guidance has Phibro Animal Health issued on next quarter's earnings?
Phibro Animal Health updated its FY19 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $1.68-1.72 for the period, compared to the Thomson Reuters consensus estimate of $1.75. Phibro Animal Health also updated its FY 2019 guidance to $1.68-1.72 EPS.
What price target have analysts set for PAHC?
3 Wall Street analysts have issued twelve-month price targets for Phibro Animal Health's shares. Their predictions range from $33.00 to $46.00. On average, they anticipate Phibro Animal Health's stock price to reach $40.3333 in the next year. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Price Targets for Phibro Animal Health.
What is the consensus analysts' recommendation for Phibro Animal Health?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 2 sell ratings and 1 hold rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Phibro Animal Health.
Has Phibro Animal Health been receiving favorable news coverage?
Media coverage about PAHC stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Phibro Animal Health earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Phibro Animal Health's key competitors?
Some companies that are related to Phibro Animal Health include Catalent (CTLT), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), Loxo Oncology (LOXO), TESARO (TSRO), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), FibroGen (FGEN), Emergent Biosolutions (EBS), Array Biopharma (ARRY), Horizon Pharma (HZNP) and Agios Pharmaceuticals (AGIO).
Who are Phibro Animal Health's key executives?
Phibro Animal Health's management team includes the folowing people:
- Mr. Jack Clifford Bendheim, Chairman, Pres & CEO (Age 71)
- Mr. Larry L. Miller, Chief Operating Officer (Age 54)
- Mr. Dean J. Warras, Pres of Animal Health & Nutrition - North America (Age 49)
- Mr. Richard G. Johnson, Chief Financial Officer (Age 69)
- Mr. Thomas G. Dagger, Sr. VP, Gen. Counsel & Corp. Sec. (Age 60)
Who are Phibro Animal Health's major shareholders?
Phibro Animal Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.61%), Vanguard Group Inc. (5.14%), Ceredex Value Advisors LLC (2.10%), Renaissance Technologies LLC (1.99%), Dimensional Fund Advisors LP (1.27%) and Fuller & Thaler Asset Management Inc. (0.97%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel A Welch, Daniel M Bendheim, Dean J Warras, Gerald K Carlson, Jack Bendheim, Larry Lee Miller, Richard G Johnson and Thomas G Dagger. View Institutional Ownership Trends for Phibro Animal Health.
Which institutional investors are selling Phibro Animal Health stock?
PAHC stock was sold by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, Panagora Asset Management Inc., Polaris Capital Management LLC, Seizert Capital Partners LLC, Allianz Asset Management GmbH, S. Muoio & CO. LLC, U S Global Investors Inc and Prudential Financial Inc.. Company insiders that have sold Phibro Animal Health company stock in the last year include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, Jack Bendheim and Larry Lee Miller. View Insider Buying and Selling for Phibro Animal Health.
Which institutional investors are buying Phibro Animal Health stock?
PAHC stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Renaissance Technologies LLC, JPMorgan Chase & Co., Assenagon Asset Management S.A., Acadian Asset Management LLC, Eagle Asset Management Inc. and Confluence Investment Management LLC. View Insider Buying and Selling for Phibro Animal Health.
How do I buy shares of Phibro Animal Health?
Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Phibro Animal Health's stock price today?
One share of PAHC stock can currently be purchased for approximately $32.62.
How big of a company is Phibro Animal Health?
Phibro Animal Health has a market capitalization of $1.32 billion and generates $820 million in revenue each year. The company earns $64.88 million in net income (profit) each year or $1.74 on an earnings per share basis. Phibro Animal Health employs 1,500 workers across the globe.
What is Phibro Animal Health's official website?
How can I contact Phibro Animal Health?
Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]
MarketBeat Community Rating for Phibro Animal Health (NASDAQ PAHC)
MarketBeat's community ratings are surveys of what our community members think about Phibro Animal Health and other stocks. Vote "Outperform" if you believe PAHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
